Cholinesterase inhibitors, a class of medicines used for treating Alzheimer’s disease, are linked to long-term reductions in cognitive decline and in the risk of death among patients, a recent study found. In fact, the cognitive benefits and reduced mortality lasted for up to five years after diagnosis, the researchers said. Among the three cholinesterase inhibitors evaluated, Razadyne(galantamine) had the strongest effect on cognitive decline — and was the only one that significantly reduced the risk…
You must be logged in to read/download the full post.
The post Cholinesterase Inhibitors Found to Slow Long-term Cognitive Decline appeared first on BioNewsFeeds.